Samsung Biologics Delays PolyPeptide Acquisition to Dec. 31, 2026

Samsung Biologics postponed its planned PolyPeptide acquisition to Dec. 31, 2026, from Nov. 30, 2026, in an Oct. 16 correction. The planned KRW 2.71 trillion acquisition covers 33,016,411 shares, representing a 100% stake, to strengthen its peptide contract development and manufacturing business. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261016000163), on October 16, 2026, and is solely responsible for the information contained therein. (C)